

BIOLOGICAL STANDARDIZATION: CODE PM E5


Bioassay of Anti-Parkinsonian Activity



Muhammad Al Shorbagy, Ph.D Pharmacology & Toxicology muhammad.alsohrbagy@pharma.cu.edu.eg

General Considerations

 Parkinson's disease is a marked deficiency in the dopaminergic innervation of the basal ganglia owing to degeneration of neurons in the substantia nigra.





Brain areas diagram



Cut section of the midbrain where a portion of the substantia nigra is visible







 1. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Model

2. Rotenone-induced Parkinson-like Symptoms

1. MPTP Model

Principle MPTP partial destruction of basal ganglia symptoms of Parkinson's disease Neurotoxin impaired (MPP+) movement, posture, balance, coordination

1. MPTP Model

Procedure before each administration of MPTP Regimen **Vehicle** Standard Test 1. Adult rhesus monkeys 2. Mice **MPTP** 5–8 days cumulative intravenous doses

1. MPTP Model

Evaluation


parkinsonism like disorder

scale of 0 (normal) to 17 (maximum severity)

- akinesia [loss of voluntary movement]
- rigidity
- postural tremor
- flexed posture
- eyelid closure
- drooling= salivation


1. MPTP Model

Evaluation




2. Rotenone-induced Parkinson-like Symptoms

Principle



2. Rotenone-induced Parkinson-like Symptoms

Procedure




2. Rotenone-induced Parkinson-like Symptoms

Evaluation


Animals are placed on a **Perspex container** situated on a

Panlab proximity sensor unit



Procedure: Apparatus

A Perspex chamber with a hinged lid.



A narrower compartment with a central platform running along its length, creating a trough on either side,

A removable double staircase is inserted into the end of the box. sliding into the troughs on either side of the central platform.

2. Rotenone-induced Parkinson-like Symptoms

Evaluation

Antiparkinsonians

- ♠ Locomotion/10min
- ♠ Rearing Number/10min
- ♠ Grooming Number/10min